SCHEMBL76596

SCHEMBL76596

O=C=Nc1ccc(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
HPGD P15428 1/20 0.40
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
TRPA1 O75762 1/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
MPI P34949 1/20 0.38
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.36
CA3 P07451 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29533142 1.00 ALDH1A1 (0.40) ALDH1A1CYP3A4TDP1HPGDCES2
SCHEMBL7733603 0.91 CYP3A4 (0.41) ALDH1A1CYP3A4TDP1HPGDCES2
SCHEMBL8590726 0.88 CYP3A4 (0.39) ALDH1A1CYP3A4TDP1HPGDCES2
SCHEMBL546406 0.83 CYP3A4 (0.39) ALDH1A1CYP3A4TDP1HPGDCES2
SCHEMBL29574772 0.83 CYP3A4 (0.39) ALDH1A1CYP3A4TDP1HPGDCES2
SCHEMBL9630076 0.81 CYP3A4 (0.55) ALDH1A1CYP3A4TDP1HPGDTRPA1
SCHEMBL420514 0.79 CYP3A4 (0.48) ALDH1A1CYP3A4TDP1HPGDTRPA1
SCHEMBL1946132 0.79 CYP3A4 (0.38) ALDH1A1CYP3A4TDP1HPGDTRPA1
SCHEMBL20798330 0.79 CYP3A4 (0.38) ALDH1A1CYP3A4TDP1HPGDTRPA1
SCHEMBL1944267 0.79 TDP1 (0.42) ALDH1A1CYP3A4TDP1HPGDTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12604597-B2 Perovskite solar cell and manufacturing method HUBEI WONDER SOLAR LIMITED LIABILITY COMPANY (CN) 2026-04-14 US claimed
EP-4521905-A1 PEROVSKITE SOLAR CELL AND MANUFACTURING METHOD Hubei Wonder SOLAR Limited Liability Company (CN) 2025-03-12 EP claimed
US-20240431125-A1 PEROVSKITE SOLAR CELL AND MANUFACTURING METHOD HUBEI WONDER SOLAR LIMITED LIABILITY COMPANY (CN) 2024-12-26 US claimed
CN-118253468-A Method for preparing coating, coating and device 江苏菲沃泰纳米科技股份有限公司 2024-06-28 CN claimed
CN-117295372-A Perovskite solar cell and preparation method thereof 武汉万度光能研究院有限责任公司 2023-12-26 CN claimed
US-20230339973-A1 RING-FUSED 2-PYRIDONE COMPOUNDS, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA QURETECH BIO AB (SE) 2023-10-26 US claimed
CN-116769094-A Binuclear vanadium catalyst containing binghAC ligand, and preparation method and application thereof 合肥工业大学 2023-09-19 CN claimed
CN-116525948-A Method for inhibiting corrosion of aluminum foil of lithium battery current collector based on isocyanate additive 临沂大学 2023-08-01 CN claimed
US-20230233536-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA QURETECH BIO AB (SE) 2023-07-27 US claimed
US-20230115208-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS QURETECH BIO AB (SE) 2023-04-13 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
EP-1003775-B1 HEPATITIS C INHIBITOR PEPTIDES BOEHRINGER INGELHEIM CA LTD (CA) 2005-03-16 EP claimed
EP-1012180-B1 HEPATITIS C INHIBITOR PEPTIDE ANALOGUES BOEHRINGER INGELHEIM CA LTD (CA) 2004-12-01 EP claimed
US-6143715-A FOR TREATING AND PREVENTION OF HEPATITIS C VIURS INFECTIONS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-11-07 US claimed
EP-1012180-A2 HEPATITIS C INHIBITOR PEPTIDE ANALOGUES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-06-28 EP claimed
EP-1003775-A2 HEPATITIS C INHIBITOR PEPTIDES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-05-31 EP claimed
WO-1999007733-A2 HEPATITIS C INHIBITOR PEPTIDES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1999-02-18 WO claimed
WO-1999007734-A2 HEPATITIS C INHIBITOR PEPTIDE ANALOGUES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1999-02-18 WO claimed
EP-0471236-B1 Imidazopyridine derivatives and their use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-03-15 EP claimed
EP-0054217-B1 ANTHRAQUINONE DYES, PROCESS FOR THEIR PREPARATION, THEIR USE, AS WELL AS LIQUID-CRYSTAL MATERIAL CONTAINING ANTHRAQUINONE DYES BAYER AG (DE) 1984-06-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115208-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF TUBERCULOSIS IL17A, TBCB, TBC1D15 ALDH1A1 1018/4885CYP3A4 229/4885TDP1 3545/4885
US-20230339973-A1 RING-FUSED 2-PYRIDONE COMPOUNDS, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA PGLS, BLVRB, SDHB ALDH1A1 2766/4885CYP3A4 1963/4885TDP1 3402/4885
US-12604597-B2 Perovskite solar cell and manufacturing method CDH1, SCNN1B, MSMO1 ALDH1A1 4242/4885CYP3A4 422/4885TDP1 2429/4885
US-20230233536-A1 RING-FUSED THIAZOLINO 2-PYRIDONES, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA NOD2, TLR4, TLR5 ALDH1A1 2321/4885CYP3A4 2115/4885TDP1 2634/4885
US-20240431125-A1 PEROVSKITE SOLAR CELL AND MANUFACTURING METHOD BRSK1, PRDM9, EYA3 ALDH1A1 2150/4885CYP3A4 639/4885TDP1 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.